Lakefront Biotherapeutics
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Lakefront Biotherapeutics sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Lakefront Biotherapeutics: 15 sponsored US clinical trials, 1 recruiting.
Lakefront Biotherapeutics sponsors 15 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 6 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage).
Top-decile sponsor footprint
Lakefront Biotherapeutics ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
7 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (50.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
15 total, page 1 of 1
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
NCT06652633
A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
NCT05479058
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects
NCT04532567
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
NCT03976648
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03864627
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
NCT03798366
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
NCT03711162
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
NCT03733444
A Study to Assess Efficacy and Safety of GLPG1972/S201086 in Participants With Knee Osteoarthritis
NCT03595618
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
NCT03201445
A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis
NCT03119649
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
NCT02914600
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
NCT02914561
Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)
NCT01894516
Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)
NCT01888874
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
| Phase 3 | 6 |
What is open in the Lakefront Biotherapeutics pipeline
1 recruiting of 15 indexed (7% open); 7 completed (47%).
Phase mix: 6 late (III/IV) vs 9 early (I/II) (balanced across stages).
Therapeutic area indexing for this sponsor is limited in the public registry.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lakefront Biotherapeutics: open-pipeline peers nationwide
Peers matched on 15 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Lakefront Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Baylor Breast Care Center · 7% recruiting · 15 trials
- Geron Corporation · 7% recruiting · 15 trials
- Guerbet · 7% recruiting · 15 trials
- Joanne Kurtzberg, MD · 7% recruiting · 15 trials
Related
What to do with this Lakefront Biotherapeutics page
15 registered trials is a research-attention snapshot, not an endorsement of Lakefront Biotherapeutics or any single study.
- 1 of Lakefront Biotherapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Lakefront Biotherapeutics pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.